← Leaderboards
Sade Monique Spencer
Ut Southwestern Medical Center
$3,280,441
Attributed
$3,280,441
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $731.3K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,280,441 · 6
By mechanism
R01$1,674,683 · 1
R00$755,221 · 1
R21$426,250 · 1
K99$266,736 · 1
F32$105,724 · 1
F31$51,827 · 1
Top collaborators
No co-investigators on record.
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Aylin Rachel Rodan$5,931,574
- John Michael Abrams$13,429,289
- Kevin W Williams$7,351,927
- Benjamin P. Weaver$3,649,800
- Elena Piskounova$2,655,797
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsNucleus AccumbensBrainMediatingCuesNeuroadaptationChronicSynaptic PlasticityIn VivoBehavioralAbstinenceTransmission ProcessRelapseDesignNeurobiologyNovel TherapeuticsResponseSynapsesSelf AdministrationGlutamatesBehaviorRattusNeurobiological MechanismCocaine
Grant awards (15)
Glutamatergic plasticity that drives cannabinoid withdrawal and craving$601,121
R01 · FY2025 · DA · contact PI
Glutamatergic plasticity that drives cannabinoid withdrawal and craving$536,027
R01 · FY2024 · DA · contact PI
Glutamatergic plasticity that drives cannabinoid withdrawal and craving$537,535
R01 · FY2023 · DA · contact PI
Targeting adenosine monophosphate activated protein kinase (AMPK) to reduce cocaine relapse$193,750
R21 · FY2023 · DA · contact PI
Targeting adenosine monophosphate activated protein kinase (AMPK) to reduce cocaine relapse$232,500
R21 · FY2022 · DA · contact PI
The role of dopamine in modulating relapse-induced transient synaptic plasticity$249,000
R00 · FY2020 · DA · contact PI
The role of dopamine in modulating relapse-induced transient synaptic plasticity$249,000
R00 · FY2019 · DA · contact PI
The role of dopamine in modulating relapse-induced transient synaptic plasticity$8,221
R00 · FY2019 · DA · contact PI
The role of dopamine in modulating relapse-induced transient synaptic plasticity$249,000
R00 · FY2018 · DA · contact PI
The Role of Dopamine in Modulating Relapse-induced Transient Synaptic Plasticity$133,368
K99 · FY2017 · DA · contact PI
The Role of Dopamine in Modulating Relapse-induced Transient Synaptic Plasticity$133,368
K99 · FY2016 · DA · contact PI
Role of Alpha2delta-1 in Cocaine Relapse and Gabapentin Mechanisms of Action$54,194
F32 · FY2015 · DA · contact PI
Role of Alpha2delta-1 in Cocaine Relapse and Gabapentin Mechanisms of Action$51,530
F32 · FY2014 · DA · contact PI
The role of dopaminergic transmission in the development of manic-like behaviors$23,468
F31 · FY2011 · MH · contact PI
The role of dopaminergic transmission in the development of manic-like behaviors$28,359
F31 · FY2010 · MH · contact PI